The report on Johnson & Johnson was published on April 11, 2026. Share the report or generate your own report on Finsight Alpha.

Johnson & Johnson logo

Johnson & Johnson

Neutral
Ticker: JNJ · https://www.jnj.com

Executive Summary

Investors are left to consider whether Johnson & Johnson can sustain its recent stock rally amid rising operational costs and competitive pressures in the healthcare sector. The company has demonstrated strong revenue growth, with earnings per share reported at $11.04, but faces significant challenges from increasing input costs and regulatory scrutiny, particularly regarding its talc-based products.

While Johnson & Johnson's recent product launches, such as the VARIPULSE Pro and new clinical data for TECNIS PureSee IOL, signal innovation and potential market expansion, the sustainability of the stock's upward momentum remains uncertain. Analysts have noted the stock's impressive 17% increase year to date, yet concerns linger about the upcoming earnings report, which could either reinforce investor confidence or reveal weaknesses that may dampen enthusiasm.

Given the interplay of strong financial performance against rising costs and regulatory risks, the outlook for Johnson & Johnson is cautiously optimistic but fraught with potential pitfalls. Therefore, the overall assessment of the investment landscape is best described as Neutral.

Next reported earnings: Tuesday, 14 April 2026, before market open.

Johnson & Johnson 6-Month Share Price

Key Metrics

Market Cap $574.66 B i
6-Month Share Price Change 25.03% i
Revenue (TTM) $94.19 B i
EBITDA (TTM) $39.90 B i
EPS (TTM) $11.04 i
Operating Cash Flow (TTM) $24.53 B i
Free Cash Flow (TTM) $19.70 B i
Cash and cash equivalents $19.71 B i
P/E Ratio (TTM) 21.61 i
Price/Book (TTM) 7.10 i
Debt/Equity 0.59 i
Current Ratio 1.03 i
Dividend Yield (TTM) 2.18% i

Tap or click the i icon for a metric definition.

The Johnson & Johnson Story

Founded in 1886 and headquartered in New Brunswick, New Jersey, Johnson & Johnson has built a diverse portfolio centered on consumer health products, pharmaceuticals, and medical devices. The company initially gained recognition for its innovative surgical dressings and antiseptic products, which addressed critical needs in healthcare.

Over the decades, Johnson & Johnson expanded its reach through strategic acquisitions and product launches. Notable milestones include the introduction of the first commercial baby powder in 1894 and the launch of Band-Aid adhesive bandages in 1920. These innovations solidified its reputation as a household name in consumer health.

In recent years, the company has pivoted towards biotechnology and advanced pharmaceuticals, focusing on areas such as immunology and oncology. This shift reflects a broader trend in the healthcare industry, where personalized medicine and targeted therapies are gaining traction. However, Johnson & Johnson's commitment to consumer health remains strong, as evidenced by its continued investment in over-the-counter products.

As the company navigates regulatory challenges and public scrutiny, particularly regarding its talc-based products, it remains focused on maintaining its legacy while adapting to the evolving healthcare landscape. Johnson & Johnson's ability to balance innovation with consumer trust will be crucial as it moves forward.

Macro Industry Position

Technological advancements and regulatory changes are pivotal forces shaping the Drug Manufacturers - General industry within the Healthcare sector. Companies in this space, including global leader Pfizer, specialist Amgen, and adjacent substitute GlaxoSmithKline, face a landscape defined by payer and reimbursement pressures. These pressures stem from evolving healthcare policies and the increasing demand for cost-effective treatments, influencing how companies develop and market their products.

Johnson & Johnson's operations are significantly impacted by its input costs, particularly in research and development, which are essential for its diverse product lines in consumer health, pharmaceuticals, and medical devices. The company's focus on biotechnology and advanced pharmaceuticals positions it against competitors like Merck and AbbVie. As Johnson & Johnson continues to innovate, it must also navigate the complexities of supply chain management and pricing strategies to maintain its competitive edge.

The financing conditions for the Drug Manufacturers - General industry are currently characterized by steady credit availability, which supports ongoing investment in research and development. However, rising employment costs and regulatory risks could temper the pace of investment. As consumer prices remain elevated, companies must balance their operational expenses with the need to deliver affordable healthcare solutions, impacting their long-term growth strategies.

Johnson & Johnson's financial health is closely tied to long-dated government yields, which influence the cost of capital for research and development initiatives. The US 10-year yield stands at 4.29 percent, unchanged, affecting how the company finances its innovation pipeline. Meanwhile, the Fed-funds rate remains at 3.64 percent, also unchanged, which stabilizes borrowing costs but may limit aggressive investment strategies. In addition, US inflation is currently at 3.3 percent year over year, reflecting ongoing pressures on operational costs, while employment costs and regulatory risks continue to challenge the industry.

Bottom line: Johnson & Johnson operates in a complex environment marked by payer and reimbursement pressures, rising employment costs, and a steady cost of capital for research and development. The current macroeconomic indicators suggest that while inflation remains a concern, stable financing conditions may support ongoing investment in innovation. However, the company must remain vigilant in managing its operational expenses to ensure it can deliver affordable healthcare solutions while pursuing long-term growth strategies.

Recent Developments

On April 7, 2026, Johnson & Johnson launched the VARIPULSE Pro in Europe, enhancing its pulsed field ablation portfolio. This product aims to improve treatment options in the electrophysiology market, which focuses on heart rhythm disorders. The introduction of VARIPULSE Pro is part of Johnson & Johnson's strategy to expand its medical device offerings and strengthen its position in this competitive sector [1].

On April 8, 2026, analysts recommended buying Johnson & Johnson stock ahead of the upcoming earnings report, suggesting that the stock's upward momentum was not yet over. The recommendation was based on the company's strong performance and positive market sentiment, which had driven the stock price up significantly in recent months [2]. Additionally, the same day, Johnson & Johnson's Tremfya regained the top position in television drug advertising spending, surpassing AbbVie, indicating a strong marketing push for this product [3].

On April 10, 2026, Johnson & Johnson's stock was reported to be up 17% year to date and over 60% in the past twelve months. This increase reflected renewed investor confidence but also raised concerns about the sustainability of the rally. The company was preparing for its first-quarter earnings report, which was anticipated to provide insights into its drug pipeline and growth prospects [4][5]. Furthermore, Johnson & Johnson showcased new clinical data for its TECNIS PureSee IOL at the ASCRS 2026 conference, highlighting its excellent contrast sensitivity and extended range of vision [6].

For investors, these updates suggest a period of growth and potential opportunity for Johnson & Johnson. The launch of new products and strong stock performance indicate positive momentum, although concerns about competition and pricing pressures remain. The upcoming earnings report on April 11, 2026, will be critical in assessing the company's financial health and future direction [7][8][9].

Sources

  • [1] Johnson & Johnson Advances Pulsed Field Ablation Portfolio with the Launch of VARIPULSE Pro in Europe - Johnson & Johnson (Apr 7, 2026)
  • [2] Buy Johnson & Johnson Stock Ahead of Earnings, Analyst Says. The Run-Up Isn’t Over. - Barron's (Apr 8, 2026)
  • [3] J&J's Tremfya retakes TV drug ad spending crown from AbbVie - Fierce Pharma (Apr 8, 2026)
  • [4] Johnson & Johnson Q1 Earnings Preview: Time To Sell The Rally? (Apr 10, 2026)
  • [5] Should You Buy, Sell or Hold JNJ Stock Ahead of Q1 Earnings? (Apr 9, 2026)
  • [6] Johnson & Johnson Showcases New Clinical Data for TECNIS PureSee IOL at ASCRS 2026 Demonstrating Excellent Contrast Sensitivity and Extended Range of Vision (Apr 10, 2026)
  • [7] Johnson & Johnson Q1 Earnings Preview: Time To Sell The Rally? - Seeking Alpha (Apr 10, 2026)
  • [8] How The Narrative On Johnson & Johnson (JNJ) Is Shifting With New Targets And Litigation Risks - Yahoo Finance (Apr 10, 2026)
  • [9] Gear Up for Johnson & Johnson (JNJ) Q1 Earnings: Wall Street Estimates for Key Metrics (Apr 9, 2026)

Financial Deep-Dive

Welcome to the Financial Deep-Dive. The eight tabs below organise Johnson & Johnson's financial data into valuation, profitability, per-share data, leverage, liquidity, efficiency, working-capital, and R&D. Each tab presents financial metrics and trend charts for its category, along with key strengths and weaknesses. Click on any measure for a clear definition and insight into its relevance for investors. At the bottom, you'll find a detailed Financial Health Summary outlining Johnson & Johnson's financial condition based on their most recent accounts.

Valuation and Market Multiples

  • Market capitalization: $574.66 B (status: green)
  • Price-to-earnings ratio: 21.61 (status: amber)
  • Price-to-sales ratio: 6.10 (status: red)
  • Price-to-book ratio: 7.10 (status: red)
  • Enterprise-value/EBITDA multiple: 15.13 (status: red)
  • EV-to-operating-cash-flow: 24.58 (status: red)
  • EV-to-free-cash-flow: 30.61 (status: red)
  • Earnings yield: 4.63% (status: green)

Profitability Ratios

  • Net profit margin: increased over the period (status: green)
  • Return on equity (ROE): increased over the period (status: green)
  • Operating profit margin: increased over the period (status: green)
  • Gross profit margin: increased over the period (status: green)
  • Return on assets (ROA): increased over the period (status: green)
  • Return on capital employed (ROCE): increased over the period (status: green)
  • Pretax profit margin: increased over the period (status: green)
  • Return on invested capital (ROIC): increased over the period (status: green)
  • Income quality: increased over the period (status: green)
  • Return on tangible assets: increased over the period (status: green)

Per-Share and Key Metrics

  • Earnings per share (EPS): $11.04 (status: green)
  • Revenue per share: increased over the period (status: green)
  • Operating cash flow per share: increased over the period (status: green)
  • Free cash flow per share: increased over the period (status: green)
  • Cash per share: $8.28 (status: red)
  • Book value per share: $33.58 (status: green)
  • Tangible book value per share: $-7.26 (status: red)
  • Interest-bearing debt per share: $19.74 (status: red)
  • Payout ratio: 46.19% (status: green)
  • Dividend per share: $5.20 (status: green)
  • Dividend yield: 2.18% (status: green)

Leverage and Coverage Ratios

  • Debt-to-equity ratio: 0.59 (status: green)
  • Debt ratio: 0.24 (status: green)
  • Interest coverage: 26.36 (status: green)
  • Total debt to capitalization: 0.37 (status: green)
  • Long-term debt to capitalization: 0.33 (status: green)
  • Cash-flow-to-debt ratio: 0.51 (status: green)

Liquidity Ratios

  • Cash and cash equivalents: $19.71 B (status: green)
  • Current ratio: 1.03 (status: amber)
  • Quick ratio: 0.77 (status: red)
  • Cash ratio: 0.36 (status: red)

Activity and Efficiency Ratios

  • Asset turnover: decreased over the period (status: red)
  • Receivables turnover: decreased over the period (status: red)
  • Inventory turnover: decreased over the period (status: red)
  • Payables turnover: decreased over the period (status: red)
  • Fixed-asset turnover: decreased over the period (status: red)
  • Operating cash flow-to-sales ratio: increased over the period (status: green)
  • Free cash flow-to-operating cash flow ratio: increased over the period (status: green)

Working-Capital and Cycle Metrics

  • Cash conversion cycle: decreased over the period (status: green)
  • Days of sales outstanding: decreased over the period (status: green)
  • Days of inventory outstanding: decreased over the period (status: green)
  • Days of payables outstanding: decreased over the period (status: red)
  • Operating cycle: decreased over the period (status: green)

Capital-Intensity and R&D

  • R&D expense-to-revenue ratio: decreased over the period (status: green)
  • Capital expenditure-to-revenue ratio: increased over the period (status: red)
  • Capex-to-operating-cash-flow ratio: increased over the period (status: red)
  • Capex per share: increased over the period (status: red)
  • Capex-to-depreciation ratio: increased over the period (status: red)
  • Stock-based compensation-to-revenue ratio: increased over the period (status: red)

Financial Health Summary

Johnson & Johnson reported a strong financial performance for FY2025, achieving revenue of $94.19 billion and EBITDA of $39.90 billion, both significant increases from FY2024's revenue of $88.82 billion and EBITDA of $24.78 billion. In the latest quarter, the company generated revenue of $24.56 billion and EBITDA of $6.21 billion. Operating cash flow for the trailing twelve months stood at $24.53 billion, reflecting solid cash generation capabilities.

The company's market capitalization is currently $574.66 billion, with a price-to-earnings ratio of 21.61. While the earnings per share is a healthy $11.04, the price-to-sales ratio of 6.10 and price-to-book ratio of 7.10 suggest that the stock may be trading at a premium. Johnson & Johnson maintains a favorable debt-to-equity ratio of 0.59 and a robust interest coverage ratio of 26.36, indicating strong leverage management. However, liquidity appears mixed; while cash and cash equivalents total $19.71 billion, the current ratio of 1.03 and quick ratio of 0.77 raise some concerns about short-term obligations.

Despite the positive cash flow per share trend, Johnson & Johnson faces challenges with its cash conversion cycle, which has increased over the reporting period, indicating that more days are tied up in working capital. Days of inventory outstanding have also risen, suggesting potential inefficiencies in inventory management. Additionally, days of payables outstanding have increased, reflecting slower payments to suppliers, which can support cash flow but may warrant closer monitoring.

Verdict: Johnson & Johnson's financial health shows strong revenue and cash generation, but the rising cash conversion cycle and inventory days present risks that could affect operational efficiency. Investors should weigh the solid profitability metrics against these working capital challenges.

Risks and Concerns

Johnson & Johnson faces significant operational risks as it navigates rising input costs, particularly in research and development. The company's shift towards biotechnology and advanced pharmaceuticals requires substantial investment, which is increasingly pressured by a competitive landscape. With competitors like Merck and AbbVie also vying for market share, Johnson & Johnson must effectively manage its supply chain and pricing strategies to maintain its edge.

Market dynamics further complicate the situation. The Drug Manufacturers - General industry is experiencing payer and reimbursement pressures, driven by evolving healthcare policies and the demand for cost-effective treatments. As consumer prices remain elevated, Johnson & Johnson must balance operational expenses with the need to deliver affordable healthcare solutions, which could impact its long-term growth strategies.

For shareholders, the upcoming earnings report will be pivotal. Johnson & Johnson's stock has surged 17% year to date and over 60% in the past twelve months, reflecting renewed investor confidence. However, this rally raises questions about sustainability amid rising employment costs and regulatory risks. If the earnings report reveals weaknesses in its drug pipeline or operational efficiency, it could challenge investor sentiment and lead to a reassessment of the stock's valuation.

Outlook

As Johnson & Johnson prepares for its upcoming earnings report, investors are keenly aware of the company's ability to maintain its recent stock rally amidst rising operational costs and competitive pressures. The company's strategic pivot towards biotechnology and advanced pharmaceuticals positions it well for growth, particularly in immunology and oncology. However, this focus comes with increased research and development expenses, which could impact profitability if not managed effectively.

Moreover, Johnson & Johnson's strong performance in consumer health products remains a cornerstone of its business model. The recent launch of the VARIPULSE Pro and the resurgence of Tremfya in advertising spending highlight the company's commitment to innovation. Still, the healthcare landscape is fraught with challenges, including payer pressures and regulatory scrutiny, particularly regarding its talc-based products. Investors should closely monitor the upcoming earnings report for insights into how these factors will shape the company's financial health and growth trajectory.

Red & Green Flags

This section distills all of the report's positives (green flags), negatives (red flags) and open questions (unknowns) into one place. The Overall view reflects a read of the evidence across the full report; it is not a simple tally of the lists below.

Green Flags

  • Johnson & Johnson has a market capitalization of $574.66 billion, indicating strong market presence.
  • The company reported a revenue of $94.19 billion for FY2025, a significant increase from FY2024's revenue of $88.82 billion.
  • EBITDA for FY2025 was $39.90 billion, up from $24.78 billion in FY2024.
  • Earnings per share is a healthy $11.04.
  • Net profit margin, return on equity, operating profit margin, gross profit margin, return on assets, return on capital employed, pretax profit margin, return on invested capital, income quality, and return on tangible assets all increased over the period.
  • Johnson & Johnson's debt-to-equity ratio is favorable at 0.59, indicating strong leverage management.
  • The company has a robust interest coverage ratio of 26.36.
  • Cash and cash equivalents total $19.71 billion, reflecting solid liquidity.
  • The launch of VARIPULSE Pro enhances its medical device offerings.
  • Tremfya regained the top position in television drug advertising spending, indicating strong marketing efforts.
  • The stock is up 17% year to date and over 60% in the past twelve months, reflecting renewed investor confidence.

Red Flags

  • The price-to-sales ratio of 6.10 and price-to-book ratio of 7.10 suggest the stock may be trading at a premium.
  • The current ratio of 1.03 and quick ratio of 0.77 raise concerns about short-term obligations.
  • The cash conversion cycle has increased, indicating inefficiencies in working capital management.
  • Days of inventory outstanding have risen, suggesting potential inefficiencies in inventory management.
  • Days of payables outstanding have increased, reflecting slower payments to suppliers, which may warrant closer monitoring.
  • Rising input costs, particularly in research and development, pose significant operational risks.
  • The competitive landscape is intensifying with rivals like Merck and AbbVie, increasing pressure on market share.
  • Payer and reimbursement pressures are complicating market dynamics, impacting long-term growth strategies.

Unknowns

  • The sustainability of the recent stock rally remains uncertain amid rising employment costs and regulatory risks.
  • The upcoming earnings report will be pivotal in assessing the company's drug pipeline and operational efficiency.

11 green flags, 8 red flags, 2 unknowns.

Overall view: Neutral.

Why this view:

  • Johnson & Johnson's financial performance shows strong revenue growth but faces challenges with rising operational costs.
  • The company is navigating significant risks related to competitive pressures and regulatory scrutiny, particularly concerning its talc-based products.
  • While recent product launches indicate innovation, the sustainability of the stock's recent rally is uncertain amid potential weaknesses in the upcoming earnings report.

Action Checklist

Below are the next research steps a retail investor should consider based on this report.

Disclaimer

This Company Report is based on publicly available information and original research, and is provided for informational purposes only. It does not constitute financial, investment, or legal advice, nor an offer or solicitation to buy or sell any security. Readers should conduct their own due diligence and consult qualified advisors before making any investment decisions. Company performance can change rapidly and past results are not a guarantee of future outcomes. The author and publisher accept no responsibility for any actions taken based on this report.